SGMO News and Press, Sangamo Therapeutics Inc.

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glo...

2026-02-03 11:03:10 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript Sangamo rises as FDA grants Fast Track status to neuropathic pain asset Sangamo rises as FDA accepts rolling submission request for gene therapy ...

RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its commo...

A look at the top 10 most actives in the United States ProShares UltraShort Silver -2x Shares (ZSL) rose 0.6% to $1.58 on volume of 896,431,943 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 0.0% to $1.76 on volume of 615,580,584 shares Signing Day Sports Inc. (SGN) rose 33....

A look at the top 10 most actives in the United States ProShares UltraShort Silver -2x Shares (ZSL) rose 7.9% to $1.6933 on volume of 822,800,987 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.3% to $1.8001 on volume of 569,291,596 shares Signing Day Sports Inc. (SGN) rose...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene...

2025-12-08 14:46:32 ET Since my article , "Regeneron: Strong R&D Pipeline Drives Growth Outlook," Regeneron Pharmaceuticals shares (NASDAQ: REGN ) have finally broken out of the accumulation phase, rising 27.4% to $718.4.... Read the full article on Seeking Alpha For...

2025-12-02 09:16:45 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript Sangamo rises as FDA accepts rolling submission request for gene therapy Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirm...

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ST-503, an investigational epigenetic regulator for the treatment of in...

2025-11-21 09:12:07 ET More on Sangamo Therapeutics Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript Sangamo targets Q1 2026 BLA submission for Fabry gene therapy as FDA affirms accelerated pathway Sangamo Therapeutics GAAP EPS of -$0.11 misses by $...